Liraglutide Injection — FDA Drug Shortage

To Be Discontinued — Novo Nordisk, Inc.

The FDA lists a drug shortage record for Liraglutide Injection (injection) from Novo Nordisk, Inc. with status To Be Discontinued. The shortage was first posted on Aug 25, 2026.

Shortage details

Status
To Be Discontinued
Company
Novo Nordisk, Inc.
Package NDC
0169-2800-15
Dosage Form
Injection
Presentation
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
Initial Posting
Aug 25, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.